These findings establish a mechanistic basis for targeting the STAT3-PLXNC1-miR-92b-5p axis, with EGCG proposed as a potential synergistic partner for immune checkpoint inhibitors to overcome immunotherapy resistance in gastric cancer. This evidence concerns the gene PLXNC1 and gastric cancer.